Keyphrases
Phase II Trial
100%
Metabotropic Glutamate Receptor
100%
Advanced Melanoma
100%
Riluzole
100%
GRM1
100%
Tumor
50%
Leukocytes
25%
Pharmacokinetic Analysis
25%
Tumor Biopsy
25%
Therapeutic Target
25%
Adverse Events
25%
Response Rate
25%
Clinical Benefit
25%
Objective Response
25%
AKT1
25%
Human Melanoma
25%
Stable Disease
25%
Biologic Activity
25%
Enhanced Bioavailability
25%
Accruals
25%
Angiogenic Markers
25%
Inter-patient Variability
25%
Active Edge
25%
Medicine and Dentistry
Phase II Trials
100%
Metabotropic Receptor 1
100%
Riluzole
100%
Melanoma
100%
Downregulation
50%
Adverse Event
25%
Neoplasm
25%
Leukocyte
25%
Mitogen-Activated Protein Kinase
25%
Pharmacokinetics
25%
Bioavailability
25%
Tumor Biopsy
25%
Protein Kinase B
25%
Tumor
25%
Diseases
25%
Pharmacology, Toxicology and Pharmaceutical Science
Melanoma
100%
Phase II Trials
100%
Metabotropic Receptor 1
100%
Riluzole
100%
Neoplasm
50%
Adverse Event
25%
Bioavailability
25%
Protein Kinase B
25%
Pharmacokinetics
25%
Diseases
25%
Biochemistry, Genetics and Molecular Biology
Phase II Trials
100%
Metabotropic Glutamate Receptor 1
100%
Riluzole
100%
Downregulation
50%
Leukocyte
25%
Pharmacokinetics
25%
Mitogen-Activated Protein Kinase
25%
Protein Kinase B
25%